8-KOther Events

PFIZER INC 8-K Report (Dec 14, 1999)

Filed December 14, 1999For Securities:PFE

Summary

Pfizer Inc. filed an 8-K report on December 14, 1999, to disclose the publication of an advertisement on December 8, 1999, regarding its proposed merger with Warner-Lambert Company. This advertisement, which appeared in major financial publications like The New York Times and The Wall Street Journal, is incorporated by reference as an exhibit to this filing. Investors should note that this filing primarily serves to formally document the dissemination of information related to the significant proposed merger. While the 8-K itself does not provide new financial data or operational updates, the advertisement discussed is a key piece of communication regarding a major strategic event for Pfizer at the time. The report also includes a standard cautionary statement about forward-looking statements, reminding investors of the inherent risks and uncertainties associated with such statements and advising them to consult other SEC filings for a comprehensive understanding of potential risk factors.

Key Highlights

  • 1Pfizer Inc. filed an 8-K on December 14, 1999.
  • 2The filing references an advertisement published on December 8, 1999.
  • 3The advertisement discusses Pfizer's proposed merger with Warner-Lambert Company.
  • 4The advertisement was published in major news outlets including The New York Times and The Wall Street Journal.
  • 5The advertisement is incorporated as Exhibit 99.1 to the 8-K filing.
  • 6The report includes a disclaimer regarding forward-looking statements and associated risks.

Frequently Asked Questions

The main purpose of this 8-K filing is to formally report and incorporate by reference an advertisement published by Pfizer on December 8, 1999. This advertisement discussed the company's proposed merger with Warner-Lambert Company.

The advertisement, published in major financial news publications, likely provided details and promoted the strategic rationale or terms related to Pfizer's proposed merger with Warner-Lambert Company. The 8-K filing itself does not contain the full content of the ad but refers to it as an exhibit.

No, this 8-K filing does not contain new financial results or specific operational updates. Its primary focus is on documenting the communication regarding the proposed merger with Warner-Lambert Company.

The disclaimer indicates that the report may contain statements about future expectations or events that involve risks and uncertainties. Actual results could differ materially from these forward-looking statements. Investors are advised to review Pfizer's other SEC filings for a detailed understanding of the risk factors that could impact the company's performance.